These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 34775496)

  • 1. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1.
    Ye S; Hu X; Sun S; Su B; Cai J; Jiang J
    Eur J Pharmacol; 2024 Jul; 974():176620. PubMed ID: 38685305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Honokiol enhances the sensitivity of cetuximab in KRAS
    Zhu Q; Zhang R; Gu X; Zhao Z; Gao Q; Chen M; Wu Q; Xie T; Sui X
    Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
    Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
    Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRF2 inhibits RSL3 induced ferroptosis in gastric cancer through regulation of AKR1B1.
    Li X; Qian J; Xu J; Bai H; Yang J; Chen L
    Exp Cell Res; 2024 Sep; 442(1):114210. PubMed ID: 39154929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
    Zhou X; Kang J; Zhang L; Cheng Y
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):119-134. PubMed ID: 37318525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells.
    Wei R; Zhao Y; Wang J; Yang X; Li S; Wang Y; Yang X; Fei J; Hao X; Zhao Y; Gui L; Ding X
    Int J Biol Sci; 2021; 17(11):2703-2717. PubMed ID: 34345202
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
    J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esculin induces endoplasmic reticulum stress and drives apoptosis and ferroptosis in colorectal cancer via PERK regulating eIF2α/CHOP and Nrf2/HO-1 cascades.
    Ji X; Chen Z; Lin W; Wu Q; Wu Y; Hong Y; Tong H; Wang C; Zhang Y
    J Ethnopharmacol; 2024 Jun; 328():118139. PubMed ID: 38561058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
    Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
    Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF
    Georgiou A; Stewart A; Vlachogiannis G; Pickard L; Valeri N; Cunningham D; Whittaker SR; Banerji U
    Cell Oncol (Dordr); 2021 Oct; 44(5):1197-1206. PubMed ID: 34462871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.